DK2776455T3 - Kanalrhodopsiner til optisk kontrol af celler - Google Patents

Kanalrhodopsiner til optisk kontrol af celler Download PDF

Info

Publication number
DK2776455T3
DK2776455T3 DK12808926.5T DK12808926T DK2776455T3 DK 2776455 T3 DK2776455 T3 DK 2776455T3 DK 12808926 T DK12808926 T DK 12808926T DK 2776455 T3 DK2776455 T3 DK 2776455T3
Authority
DK
Denmark
Prior art keywords
light
leu
gly
ala
val
Prior art date
Application number
DK12808926.5T
Other languages
English (en)
Inventor
Edward Boyden
Gane Ka Shu Wong
Brian Yichiun Chow
Yongku Peter Cho
Nathan Klapoetke
Original Assignee
Massachusetts Inst Technology
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Univ Alberta filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK2776455T3 publication Critical patent/DK2776455T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Agression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
    • G01N33/48728—Investigating individual cells, e.g. by patch clamp, voltage clamp
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Claims (15)

1. Isoleret, lysaktiveret ionkanal-polypeptid omfattende en aminosyresekvens af et vildtype eller modificeret lysaktiveret Chlamydomonas noctigama-kanal-polypeptid, hvor aminosyresekvensen af det lysaktiverede ionkanal-polypeptid omfatter SEQ ID NO:2 eller aminosyresekvensen af det lysaktiverede ionkanal-polypeptid omfatter en modificeret Chlamydomonas noctigama lysaktiveret ionkanal-sekvens, der har mindst 70 % identitet til aminosyrer 86-320 af SEQ ID NO: 2 og mindst 95 % identitet til de resterende aminosyrer i sekvensen angivet som SEQ ID NO:2, hvorved en nukleinsyre- eller polypeptid-sekvens kan blive naturligt udtrykt i en celle eller organisme af et medlem af Chlamydomonas-s\ægten, men forudsat at sekvensen ikke er en del af eller inkluderet i en Chlamydomonas-ceWe eller -organisme, den er betragtet at være isoleret fra.
2. Polypeptidet ifølge krav 1, hvor aminosyresekvensen af det lysaktiverede ionkanal-polypeptid omfatter en modificeret Chlamydomonas noctigama lysaktiveret ionkanal-sekvens, der har mindst 75 %, 80 %, 85 %, 90 %, 95 %, eller 99 % identitet til aminosyrer 86-320 af SEQ ID NO: 2 og mindst 96 %, 97 %, 98 %, 99 % eller 100 % identitet til de resterende aminosyrer i sekvensen angivet som SEQ ID NO:2.
3. Polypeptidet ifølge krav 1, hvor aminosyresekvensen af det lysaktiverede ionkanal-polypeptid omfatter SEQ ID NO:5.
4. Polypeptidet ifølge krav 1, hvor aminosyresekvensen af det lysaktiverede ionkanal-polypeptid omfatter en modificeret Chlamydomonas noctigama lysaktiveret ionkanal-sekvens, der har mindst 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, eller 99 % identitet til aminosyrer 86-320 af SEQ ID NO: 5 og 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identitet til de resterende aminosyrer i sekvensen angivet som SEQ ID NO:5.
5. Nukleinsyre, der koder det isolerede, lysaktiverede ionkanal-polypeptid som defineret i et hvilket som helst af kravene 1-4.
6. Nukleinsyren ifølge krav 5, hvor nukleinsyresekvensen er som angivet i SEQ ID NO:3.
7. Vektor omfattende nukleinsyren ifølge krav 5 eller 6.
8. Vektoren ifølge krav 7, hvor vektoren er en ekspressionsvektor.
9. Det lysaktiverede ionkanal-polypeptid som defineret i et hvilket som helst af kravene 1-4 til anvendelse i en fremgangsmåde til medicinsk behandling af et individ.
10. Polypeptidet til anvendelse i en fremgangsmåde ifølge krav 9, hvor lidelsen er valgt fra alkalose og lidelser af synssystemet.
11. Lysaktiveret ionkanal-polypeptid ifølge et hvilket som helst af kravene 1-4, en nukleinsyre ifølge kravene 5-6, eller en vektor ifølge kravene 7-8 til anvendelse i en fremgangsmåde til behandling afen lidelse i et individ, hvilken fremgangsmåde omfatter: a) at administrere til et individ med behov for sådan behandling, en terapeutisk effektiv mængde af det lysaktiverede ionkanal-polypeptid, nukleinsyren eller vektoren, for at behandle lidelsen, hvorved administrationen resulterer i udtryk af den lysaktiverede ionkanal i en celle i individet, og b) at bringe cellen af individet i kontakt med lys og at aktivere den lysaktiverede ionkanal i cellen underforhold tilstrækkelige til at ændre ion-ledeevne af en cellemembran, hvor ændring af ledeevnen af cellemembranen behandler lidelsen.
12. Polypeptidet, nukleinsyren eller vektoren til anvendelse i en fremgangsmåde ifølge krav 11, hvor at ændre ion-ledeevnen af membranen depolariserer cellen.
13. Polypeptidet, nukleinsyre, eller vektor til anvendelse i en fremgangsmåde ifølge krav 11, hvor lidelsen er valgt fra skade, hjerneskade og degenerative neurologiske tilstande.
14. Polypeptidet, nukleinsyren eller vektoren til anvendelse i en fremgangsmåde ifølge krav 13, hvor lidelsen er valgt fra Parkinsons sygdom, Alzheimers sygdom, slagtilfælde, synstab og høretab.
15. Fremgangsmåde til at ændre ion-ledeevne af en membran, hvilken fremgangsmåde omfatter: a) at udtrykke i en værtscellemembran et lysaktiveret ionkanal-polypeptid som defineret i et hvilket som helst af kravene 1-4, og b) at bringe det lysaktiverede ionkanal-polypeptid i kontakt med et lys, der aktiverer den lysaktiverede ionkanal og ændrer ion-ledeevnen af membranen, hvor fremgangsmåden udføres in vitro.
DK12808926.5T 2011-11-12 2012-11-12 Kanalrhodopsiner til optisk kontrol af celler DK2776455T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559076P 2011-11-12 2011-11-12
PCT/US2012/064665 WO2013071231A1 (en) 2011-11-12 2012-11-12 Channelrhodopsins for optical control of cells

Publications (1)

Publication Number Publication Date
DK2776455T3 true DK2776455T3 (da) 2018-02-26

Family

ID=47470101

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17165633.3T DK3214094T3 (da) 2011-11-12 2012-11-12 Kanalrhodopsiner til optisk kontrol af celler
DK12808926.5T DK2776455T3 (da) 2011-11-12 2012-11-12 Kanalrhodopsiner til optisk kontrol af celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17165633.3T DK3214094T3 (da) 2011-11-12 2012-11-12 Kanalrhodopsiner til optisk kontrol af celler

Country Status (8)

Country Link
US (6) US10472398B2 (da)
EP (2) EP3214094B1 (da)
KR (2) KR102084803B1 (da)
DK (2) DK3214094T3 (da)
ES (2) ES2660114T3 (da)
HK (2) HK1202128A1 (da)
PL (1) PL2776455T3 (da)
WO (1) WO2013071231A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022457B2 (en) * 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US20130309278A1 (en) * 2005-08-05 2013-11-21 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
DK3214094T3 (da) * 2011-11-12 2020-07-13 Massachusetts Inst Technology Kanalrhodopsiner til optisk kontrol af celler
WO2015167639A1 (en) * 2014-02-07 2015-11-05 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof
WO2015161308A1 (en) 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
US10882892B2 (en) 2014-08-05 2021-01-05 Massachusetts Institute Of Technology Channelrhodopsin variants and uses thereof
WO2017187272A1 (en) 2016-04-29 2017-11-02 Gensight Biologics Sa Optogenetic visual restoration using chrimson
WO2017207761A1 (en) 2016-06-03 2017-12-07 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutant light-inducible ion channel of chrimson
US20190218256A1 (en) 2016-06-03 2019-07-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mutant light-inducible ion channel of channelrhodopsin
EP3472657A1 (en) 2016-06-17 2019-04-24 Sorbonne Université Device for illuminating an object with a controlled light intensity and associated method
US11278633B2 (en) 2016-07-21 2022-03-22 Massachusetts Institute Of Technology Dummy-fluorescent protein fusions and methods of use
CN110023327B (zh) * 2016-08-29 2024-02-27 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
JP6779546B2 (ja) * 2016-11-06 2020-11-04 ナノスコープ テクノロジーズ エルエルシーＮａｎｏｓｃｏｐｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
EP3422065A1 (en) 2017-06-28 2019-01-02 Gensight Biologics Objective, camera and system adapted for optogenetics comprising such objective
TWI653037B (zh) 2018-01-11 2019-03-11 友睦科技股份有限公司 可控溫的遠紅外線照射設備
KR20200106935A (ko) 2018-01-11 2020-09-15 젠사이트 바이올로직스 이벤트 기반 광센서에서 생성된 비동기 신호 처리 방법 및 장치
WO2020061079A1 (en) * 2018-09-18 2020-03-26 California Institute Of Technology Engineered light-sensitive proteins
EP3693060A1 (en) 2019-02-05 2020-08-12 Gensight Biologics Method for controlling an optogenetic device using a command law for the radiant power of a light source and associated devices
EP3693061A1 (en) 2019-02-05 2020-08-12 Gensight Biologics Method for controlling an optogenetic device using filtering and associated devices
EP3733139A1 (en) 2019-05-02 2020-11-04 Gensight Biologics Viewing apparatus and method for projecting a light signal
US11454402B1 (en) 2021-12-01 2022-09-27 Mcevoy William B Tabletop cooking assembly
EP4223768A1 (en) 2022-02-04 2023-08-09 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Novel mutant bacteriorhodopsin-like-channelrhodopsin ion channel
WO2024015705A1 (en) * 2022-07-09 2024-01-18 Bionic Sight, Llc An optogenetic gene therapy for treating blindness

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322439C (en) 1988-03-28 1993-09-28 Junji Ohyama Ion permeable membrane and ion transport method by utilizing said membrane
EP0934553A1 (de) 1996-10-25 1999-08-11 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Verfahren zur vorbereitung der erzeugung strukturierter metallschichten mit hilfe von proteinen
US7939220B2 (en) 2000-07-27 2011-05-10 Mib Munich Innovative Biomaterials Gmbh Proton-translocating retinal protein
DE10216005A1 (de) * 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
WO2007024391A2 (en) 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
AU2007247929A1 (en) 2006-05-04 2007-11-15 Pennsylvania College Of Optometry Restoration of visual responses by In Vivo delivery of rhodopsin nucleic acids
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US20110165681A1 (en) 2009-02-26 2011-07-07 Massachusetts Institute Of Technology Light-Activated Proton Pumps and Applications Thereof
US9138596B2 (en) * 2007-08-22 2015-09-22 Cardiac Pacemakers, Inc. Optical depolarization of cardiac tissue
WO2009119782A1 (ja) 2008-03-24 2009-10-01 国立大学法人東北大学 改変された光受容体チャネル型ロドプシンタンパク質
EA201001621A1 (ru) * 2008-04-18 2011-06-30 Новартис Форшунгсштифтунг, Цвайгнидерлассунг Фридрих Мишер Инститьют Фор Байомедикал Рисёрч Новые терапевтические средства и способы лечения слепоты
DE102008020152B4 (de) * 2008-04-22 2012-04-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
BRPI0911448A2 (pt) * 2008-04-23 2019-02-26 The Board Of Trustees For The Leland Stanford Junior University sistemas, métodos e composições para simulação óticas de células alvo
WO2010033230A2 (en) 2008-09-18 2010-03-25 Shai Einbinder Use of fluorescent protien in cyanobacteria and algae for improving photosynthesis and preventing cell damage
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
US10568307B2 (en) * 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
AU2011323226B2 (en) * 2010-11-05 2015-03-12 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
US20120214188A1 (en) 2010-11-12 2012-08-23 Nathan Klapoetke Light-activated ion channel molecules and uses thereof
US8957028B2 (en) 2010-11-13 2015-02-17 Massachusetts Institute Of Technology Red-shifted opsin molecules and uses thereof
DK3214094T3 (da) 2011-11-12 2020-07-13 Massachusetts Inst Technology Kanalrhodopsiner til optisk kontrol af celler

Also Published As

Publication number Publication date
US10711044B2 (en) 2020-07-14
US20190352347A1 (en) 2019-11-21
US20200291074A1 (en) 2020-09-17
EP2776455A1 (en) 2014-09-17
US11274128B2 (en) 2022-03-15
HK1202128A1 (en) 2015-09-18
ES2801679T3 (es) 2021-01-12
US20140324134A1 (en) 2014-10-30
US20200031883A1 (en) 2020-01-30
KR102194185B1 (ko) 2020-12-22
US10717769B2 (en) 2020-07-21
DK3214094T3 (da) 2020-07-13
EP2776455B1 (en) 2018-01-10
HK1243717A1 (zh) 2018-07-20
KR20140091743A (ko) 2014-07-22
US20170088590A1 (en) 2017-03-30
ES2660114T3 (es) 2018-03-20
US10472399B2 (en) 2019-11-12
WO2013071231A1 (en) 2013-05-16
PL2776455T3 (pl) 2018-07-31
EP3214094B1 (en) 2020-04-01
KR20200024336A (ko) 2020-03-06
US20220169684A1 (en) 2022-06-02
KR102084803B1 (ko) 2020-03-05
US10472398B2 (en) 2019-11-12
EP3214094A1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
US10711044B2 (en) Channelrhodopsins for optical control of cells
US10106584B2 (en) Red-shifted opsin molecules and uses thereof
US20180051058A1 (en) Light-activated chimeric opsins and methods of using the same
EP2635110B1 (en) Control and characterization of psychotic states
US20200121942A1 (en) Compositions and methods for controlling pain
US10882892B2 (en) Channelrhodopsin variants and uses thereof
US20120214188A1 (en) Light-activated ion channel molecules and uses thereof
US20170174730A1 (en) Blue light-activated ion channel molecules and uses thereof
US10590181B2 (en) Mutant channelrhodopsins with altered ion selectivity
US11542314B2 (en) Step-function channelrhodopsins for optical control of cells
EP3464342A1 (en) Mutant light-inducible ion channel of chrimson